Silexion Therapeutics (SLXN) Gains from Sales and Divestitures (2023 - 2024)
Silexion Therapeutics (SLXN) recorded Gains from Sales and Divestitures of -$16,000 in Q4 2024.
Powered by 
Analysis
Silexion Therapeutics (SLXN) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends
- Across earlier years, Gains from Sales and Divestitures came in at $1,000 in FY2023.
- The Q4 2024 figure is the highest quarterly Gains from Sales and Divestitures since Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Silexion Therapeutics | 178,711.77 | -19.70 Mn | - |
API Access
Silexion Therapeutics Gains from Sales and Divestitures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SLXN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gains-from-sales-and-divestitures", "ticker": "SLXN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SLXN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();